Drug
SCIO-469
SCIO-469 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
5
100%
Phase Distribution
0
Early Stage
5
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
5(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 25 (100.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
NCT00113893
completedphase_2
Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
NCT00095680
completedphase_2
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
NCT00087867
completedphase_2
SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
NCT00089921
completedphase_2
Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate
NCT00043732
Clinical Trials (5)
Showing 5 of 5 trials
NCT00113893Phase 2
SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
NCT00095680Phase 2
Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
NCT00087867Phase 2
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
NCT00089921Phase 2
SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
NCT00043732Phase 2
Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5